Sanara MedTech 배당금 및 환매

배당금 기준 확인 0/6

Sanara MedTech 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

0.04%

환매 수익률

총 주주 수익률	0.04%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Nov 15

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Mar 22

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Sep 06

Sanara MedTech reports Q2 results

Aug 15

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Dec 31

Sanara MedTech: Technology For Faster Healing Wounds

Dec 08

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Jun 04

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

May 18

Neil Cataldi From Blueprint Discusses Sanara MedTech

May 03

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

Feb 19

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Dec 28

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 SMTI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: SMTI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Sanara MedTech 시장 대비 배당 수익률

SMTI 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (SMTI)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Medical Equipment)	1.6%
애널리스트 예측 (SMTI) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SMTI 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SMTI 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SMTI 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: SMTI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Sanara MedTech 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Consensus estimates of losses per share improve by 30%

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Sanara MedTech Inc. Announces Changes to Its Board of Directors

Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump

Consensus EPS estimates fall by 157%, revenue upgraded

Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt

New major risk - Revenue and earnings growth

Sanara MedTech Inc. to Report Q2, 2024 Results on Aug 12, 2024

Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story

Sanara MedTech Inc. Announces CEO Changes

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.14 loss in 1Q 2023)

Sanara MedTech Inc. to Report Q1, 2024 Results on May 13, 2024

Sanara MedTech Inc., Annual General Meeting, Jun 12, 2024

Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q4, 2023 Results on Mar 25, 2024

Price target decreased by 18% to US$49.00

Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 3Q 2022)

Sanara MedTech Inc. to Report Q3, 2023 Results on Nov 13, 2023

Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sanara MedTech Inc. (NasdaqCM:SMTI) acquired Certain Assets Related to its Collagen Products Business from Applied Nutritionals, LLC, The Hymed Group Corporation, and Dr. George Petito for 25.3 million.

High number of new directors

Sanara MedTech Inc. Elects Robert Desutter as Board of Director

Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sanara MedTech Inc. to Report Q1, 2023 Results on May 15, 2023

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Forecast breakeven date pushed back to 2024

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. Announces Resignation of Shawn M. Bowman as President, Strategic Partnerships

Forecast to breakeven in 2023

Sanara MedTech Inc. to Report Q3, 2022 Results on Nov 14, 2022

President of Strategic Partnerships notifies of intention to sell stock

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech reports Q2 results

Sanara MedTech Inc. to Report Q2, 2022 Results on Aug 15, 2022

Sanara MedTech Inc acquired Scendia Biologics, LLC from Ryan Phillips for $7.4 million.

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Sanara MedTech: Technology For Faster Healing Wounds

Third quarter 2021 earnings released: US$0.27 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.18 loss in 2Q 2020)

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.39 loss in 1Q 2020)

Neil Cataldi From Blueprint Discusses Sanara MedTech

Full year 2020 earnings released: US$0.76 loss per share (vs US$1.32 loss in FY 2019)

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

New 90-day low: US$30.00

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Sanara MedTech Inc. Appoints Sara Ortwein as Director

New 90-day high: US$41.35

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day high: US$34.24

Sanara MedTech Inc Appoints Bob Desutter to the Company's Board of Directors

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기